AzTrials
AzTrials

Traumatic Brain InjuryPhase 3NCT00222742

Hypothermia in Children After Trauma

A Phase 3 study testing induced moderate hypothermia in people with Traumatic Brain Injury, run by Phoenix Children's Hospital at 30 sites in 6 countries.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The primary hypothesis for this application for a multicenter phase III randomized clinical trial (RCT) is that induced moderate hypothermia (HYPO) (32-33 °C) after severe traumatic brain injury (TBI) in children and maintained for 48 hours will improve mortality at 3 months and 12 month functional outcome as assessed… Read more about this study

Who is it for?
Ages Up to 17 years
Conditions the study is for
Traumatic Brain Injury
What is being tested?
induced moderate hypothermia
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
90 participants
Where
30 sitesin 6 countries
Study dates
Nov 2007to Mar 2012
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 17 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Patients with a GCS </= 8
  • Glasgow Motor Score < 6
  • Closed head injury
  • Age 0 < 18 y

Who cannot join

  • Unavailable to initiate cooling within 6 hours of injury
  • Glasgow Coma Scale (GCS) score = 3 and abnormal brainstem function
  • Normal initial CT scan (No blood, fracture, swelling, and/or shift)
  • Penetrating brain injury
  • No known mechanism of injury
  • Unknown time of injury
Show all 10Show fewer
  • Uncorrectable coagulopathy (PT/PTT > 16/40 sec, INR > 1.7)
  • Hypotensive episode (Systolic Blood Pressure <5th percentile for age>10 min)
  • Documented Hypoxic episode (O2 saturation < 94% for > 30 min)
  • Pregnancy

Trial locations and contacts

30 sites in 6 countries.

30 sites in 6 countries

United States17 sites
  • Carolinas Medical Center

    Charlotte, North Carolina, 28203

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio, 47229-3039

  • Nationwide Children's Hospital

    Columbus, Ohio, 43205

  • University of Texas, Southwestern

    Dallas, Texas, 75235

  • Duke University

    Durham, North Carolina, 27710

  • Penn State Hershey Medical Center

    Hershey, Pennsylvania, 17033

  • University of Miami

    Miami, Florida, 33136

  • Cohen's Children's Hospital

    New Hyde Park, New York, 11040

  • Weill Cornell Medical Center

    New York, New York, 10950

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19104

  • Phoenix Childrens Hospital

    Phoenix, Arizona, 85016

  • University of Pittsburgh/Children's Hospital of Pittsburgh

    Pittsburgh, Pennsylvania, 15213

  • Mayo Clinic in Rochester

    Rochester, Minnesota, 55905

  • University of California, Davis Medical Center

    Sacramento, California, 95817

  • University of Washington

    Seattle, Washington, 98104

  • Washington University

    St Louis, Missouri, 63110

  • Children's National Medical Center

    Washington D.C., District of Columbia, 20010

Other trials in United States

Australia7 sites
  • Royal Children's Hospital, Brisbane

    Brisbane, Queensland, 4029

  • Mater Children's Hospital

    Brisbane, Queensland, 4101

  • Children's Youth and Women's Health Service

    North Adelaide, South Australia, 5006

  • Royal Children's Hospital Melbourne

    Parkville, Victoria, 3052

  • Princess Margaret Hospital for Children

    Subiaco, Perth, Western Australia, 6008

  • Sydney Children's Hospital, Randwick

    Sydney, New South Wales, 2031

  • Children's Hospital at Westmead

    Westmead, New South Wales, 2145

Other trials in Australia

Canada2 sites
  • Stollery Children's Hospital

    Edmonton, Alberta, T6G2B7

  • British Columbia Children's Hospital

    Vancouver, British Columbia, V4A 5X3

Other trials in Canada

United Kingdom2 sites
  • Birmingham Children's Hospital

    Birmingham, West Midlands, UK B4 6NH

  • Institute of Child Health, Univ. College London & Great Ormond

    Bloomsbury, London, WC1N 3JH

Other trials in United Kingdom

New Zealand1 site
  • Starship Children's Hospital

    Auckland, 1023

Other trials in New Zealand

South Africa1 site
  • University of Cape Town

    Rondebosch, Cape Town, 7700

Other trials in South Africa

About this study

Official title: Pediatric Traumatic Brain Injury Consortium: Hypothermia

The primary hypothesis for this application for a multicenter phase III randomized clinical trial (RCT) is that induced moderate hypothermia (HYPO) (32-33 °C) after severe traumatic brain injury (TBI) in children and maintained for 48 hours will improve mortality at 3 months and 12 month functional outcome as assessed by the Glasgow Outcome Scale (GOS).

Read the detailed description

The primary specific aim of this RCT is to determine the effect of induced moderate HYPO (32-33 °C) after severe TBI in children on mortality at 3 months post injury. The primary outcome measure will be the GOS; the primary time point for evaluation is 3 months. Further secondary functional outcome measures will include the GOS - Extended Pediatrics (GOS - E Peds), and Vineland Adaptive Behavior Scale (VABS) and will be assessed in conjunction with the GOS at 6 and 12 months post injury.

The secondary hypotheses are based on the results and analysis of the Pilot Clinical Trial (completed and recently published [Adelson et al. NEUROSURGERY. 56 (4): 740-754, 2005]). These secondary hypotheses include that induced moderate hypothermia (HYPO) (32-33 °C) after severe TBI in children and maintained for 48 h:

  • will improve other outcome assessments including neurocognitive status on performance-based neuropsychological testing across the domains of intellectual development, learning and memory, language, motor and psychomotor skills, visuo-spatial abilities, attention and executive function, and behavior at only 6 and 12 months after injury;
  • HYPO will improve long term outcome of all age ranges and across genders in infants, young, preadolescent, and adolescent children; AND
  • HYPO will lessen intracranial hypertension and lessen the intensity of therapy necessary for control of ICP.

Based on these hypotheses, further secondary specific aims are proposed:

  • Specific Aim 2: To determine the effect of early induced moderate HYPO (32-33°C) after severe TBI in children on global function and neurocognitive outcomes in the areas of intellectual ability/ development, memory and learning, and behavior at 6 and 12 months post injury.
  • Specific Aim 3: To determine the effect of early induced moderate HYPO after severe TBI in children of different age ranges (< 6 y and 6- < 16 y) on mortality and 6 and 12 months functional and neurocognitive outcomes.
  • Specific Aim 4: To determine the effect of early moderate HYPO after severe TBI in children on reducing intracranial hypertension and maintaining adequate cerebral perfusion pressure (CPP).
Being tested
induced moderate hypothermia
Keywords
hypothermia, pediatric TBI
Medical subject headings
Brain Injuries, Traumatic, Hypothermia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • induced moderate hypothermiaProcedure or surgery

    Subjects assigned to the treatment arm will be cooled to 32-33 °C for 48 hours and then slowly warmed.

Study groups in NCT00222742
Study groupRoleWhat they receive
AExperimentalInduced moderate hypothermia (32-33 C)
Receives: Procedure: induced moderate hypothermia

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The primary specific aim of this RCT is to determine the effect of induced moderate HYPO (32-33 °C) after severe TBI in children on mortality.

    Measured: 3 month post injury

Secondary outcomes (3)
  1. To determine the effect of HYPO after severe TBI in children on global function and neurocognitive outcomes in the areas of intellectual ability/development, memory and learning, and behavior.

    Measured: at 6 and 12 months post injury

  2. To determine the effect of HYPO after severe TBI in children of different age ranges (< 6y; 6-<16y; and 16-<18y) on mortality and 6 and 12 months functional and neurocognitive outcomes.

    Measured: 3, 6 and 12 months post injury

  3. To determine the effect of HYPO after severe TBI in children on reducing intracranial hypertension and maintaining adequate cerebral perfusion pressure (CPP).

    Measured: 7 days post injury

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Sep 2005 (estimated)
  2. Study startNov 2007
  3. Primary completionMay 2011
  4. Study completionMar 2012

Why it stopped: Futility

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
90 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00222742
Sponsor's protocol ID
1R01-NS052478-01
Other IDs
1R01NS052478-01
Status last verified
Jul 2012
First submitted
16 Sep 2005
Last updated
11 Jul 2012
Results posted
No
Data monitoring committee
Yes

Publications

  • Meinert E, Bell MJ, Buttram S, Kochanek PM, Balasubramani GK, Wisniewski SR, Adelson PD; Pediatric Traumatic Brain Injury Consortium: Hypothermia Investigators. Initiating Nutritional Support Before 72 Hours Is Associated With Favorable Outcome After Severe Traumatic Brain Injury in Children: A Secondary Analysis of a Randomized, Controlled Trial of Therapeutic Hypothermia. Pediatr Crit Care Med. 2018 Apr;19(4):345-352. doi: 10.1097/PCC.0000000000001471.

    PubMed 29370008
  • Adelson PD, Wisniewski SR, Beca J, Brown SD, Bell M, Muizelaar JP, Okada P, Beers SR, Balasubramani GK, Hirtz D; Paediatric Traumatic Brain Injury Consortium. Comparison of hypothermia and normothermia after severe traumatic brain injury in children (Cool Kids): a phase 3, randomised controlled trial. Lancet Neurol. 2013 Jun;12(6):546-53. doi: 10.1016/S1474-4422(13)70077-2. Epub 2013 May 8.

    PubMed 23664370

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing induced moderate hypothermia in people with Traumatic Brain Injury, run by Phoenix Children's Hospital at 30 sites in 6 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 11 Jul 2012. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 30 sites in United States, Australia, Canada, United Kingdom, New Zealand and 1 more country. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was stopped early (reason given: Futility). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The primary specific aim of this RCT is to determine the effect of induced moderate HYPO (32-33 °C) after severe TBI in children on mortality. (time frame: 3 month post injury). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00222742, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jul 2012.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in